



# EmphyCorp N115 Rx Nasal Spray Drug Pipeline 1/18/2022

5 Drug Patents/3 Pending incl. Hypoxemia treats all the Diseases below. (x = completed)

Disease	Drug	Phase 1	Phase 2	Phase 3	NDA	Note
<b>Pulmonary Fibrosis</b> (PF/IPF – Orphan Drug)	N115 Non-Steroidal Nasal Spray	X	X	X	→	\$3 to \$5 Billion Market
<b>COVID-19</b> Treatment & Preventative (No Adverse Effects)	N115 Non-Steroidal Nasal Spray	X	X	X		Increases Nasal NO to kill Viruses/shuts down IL-6
<b>COVID-19 Long Hauler Treatment</b> (No Adverse Effects)	N115 Non-Steroidal Nasal Spray	X	X	X		Treats Long Hauler Symptoms
<b>Influenza A&amp;B</b> Treatment & Preventative (No Adverse Effects)	N115 Non-Steroidal Nasal Spray	X	X	→		Increases Nasal NO to kill Viruses / shuts down IL-6
<b>Unmet Needs - Allergic Rhinitis, COPD</b> (Diabetic, Hypertensive, Pregnant, Child)	N115 Non-Steroidal Nasal Spray	X	X			\$24 Billion Market (30 to 60 Million People in US Alone)
<b>COPD – All Ages</b>	N115 Non-Steroidal Nasal Spray	X	X			\$4 to \$8 Billion Market
<b>Cystic Fibrosis</b> (Orphan Drug)	N115 Non-Steroidal Nasal Spray	X	X			\$3 to \$5 Billion Market
<b>Allergic Rhinitis</b> (70% Lower Steroids Version)	N115 Nasal Spray	X	X			\$2 Billion Market
<b>COPD</b> (70% Lower Steroids Version)	N115 Nasal Spray or Oral Spray	X	X			\$2 Billion Market
<b>Alzheimer’s</b>	N115 Nasal Spray	X	X			\$4 Billion Market
<b>Concussions</b>	N115 Nasal Spray	X	X			\$2 Billion Market
<b>Cancer Pre-Treatment</b>	N115 Nasal Spray	X	X			\$2 Billion Market
<b>OTC Nasal Spray sold mostly in North America and in China</b>	OTC N115 Nasal Spray	(1) US and (3) Chinese Approved Nasal Sprays				3 Million Patients Treated